{
    "data": [
        {
            "id": "4654190",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-26T09:13:34-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432461779/image_1432461779.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107143",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "504548",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "5127",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4654190-charles-river-stock-mr-market-went-from-overvaluation-to-undervaluation"
            }
        },
        {
            "id": "4650052",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-09T18:19:22-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441662840/image_1441662840.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Charles River: Q3 Points To Ongoing Deterioration",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53552",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "500506",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "5127",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4650052-charles-river-q3-points-to-ongoing-deterioration"
            }
        },
        {
            "id": "4639435",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-06T14:46:22-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441663123/image_1441663123.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Charles River Laboratories: Diving Into The Lab (Rating Upgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "491558",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "5127",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4639435-charles-rivers-laboratories-diving-into-the-lab-rating-upgrade"
            }
        },
        {
            "id": "4619800",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-26T02:05:15-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/162264253/image_162264253.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Charles River Laboratories: Very Attractive After The Pullback",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106586",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "473208",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "5127",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619800-charles-river-laboratories-very-attractive-after-the-pullback"
            }
        },
        {
            "id": "4603442",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-11T23:09:52-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1415108838/image_1415108838.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Charles River: Strong Earnings Manifest Life Science Megatrends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106766",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "455601",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "5127",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4603442-charles-river-stock-strong-q1-earnings-manifest-life-science-megatrends"
            }
        },
        {
            "id": "4581993",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-25T09:38:03-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386963233/image_1386963233.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Charles River Laboratories: Buy This Compounder After The Recent Decline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "99826",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "440214",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "5127",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4581993-charles-river-laboratories-buy-compounder-recent-decline"
            }
        },
        {
            "id": "4575510",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-06T02:37:00-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1019889202/image_1019889202.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Charles River Laboratories International: A Great Business At A Decent Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "435725",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "5127",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575510-charles-river-laboratories-international-stock-great-business-decent-price"
            }
        }
    ]
}